Atrial fibrillation is one of the leading cardiac issues in our patient population. This session reviews the pathophysiology behind the disease process, pertinent diagnostic findings, and the current pharmacologic management of this process.
Contact hours available until 4/24/2015
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation.
Faculty, Planners and Authors Conflict of Interest Disclosure: Planning Committee: Kristin Larson – Consultant, Nephrology Clinical Solutions; Employee, Affymax; Other financial support, Kristin M. Larson, RN, MSN, LLC; Sandy Bodin – Employee, Affymax; Dawn Koonkongsatian – Employee, Fresenius Medical Care; Elizabeth St. John - Employee, Fresenius Medical Care
Presenter(s) have no disclosures to declare.
Commercial Support and Sponsorship: No commercial support or sponsorship declare.
Non-Endorsement of Products: Accreditation of activities for contact hours does not imply approval or endorsement of any product, advertising, or educational content by ANNA or the American Nurses Credentialing Center’s Commission on Accreditation.
Accreditation Statement: American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.
Objectives: • Describe risk factors for developing atrial fibrillation. • Describe treatment options - both medical and surgical - for atrial fibrillation. • Identify where to access guidelines for management of atrial fibrillation.
MS, CNP, CHFN,
University of MN Health
You must be logged in and own this session in order to
12/31/16 4:09 pm
I felt the information was very Essential to the topic. I gaind alot of knowledge.